Your chart gives one star to CR and 3 stars for rapa if given late in life. This is incorrect. CR certainly doesn’t work as well at increasing absolute lifespan when started late than when started earlier, but the magnitude of the remaining lifespan increase is similar when started in old vs. young, and the absolute or remaining increase is greater for CR than it is for rapa when started at the same age. Compare:
40% CR initiated at 19 months of age
“CR extended mean lifespan from 30.7 ± 0.7 (SE) to 35.4 ± 0.8 months (P = .000017) and extended maximum lifespan from 37.6 to 43.6 months (P = 0.000056)”
Rapamycin begun at 19-20 months of age (ITP)
“Expressed as mean lifespan, the effect sizes were 9% for males and 13% for females in the pooled data set.”
Masimum lifespan
Females
Rapamycin 1,245 versus controls 1,094
Males
Rapamycin 1,179 versus controls 1,078
Note also that the mice in the CR study were male, and that the extension of lifespan was greater than for either male or female mice given rapamycin.
(Yes, two different studies, different mouse hybrids, etc. Still).